Pfizer Looks To Combination Regimens To Maximize Oncology Pipeline Value
Executive Summary
Pfizer is seeking to maximize the value of its oncology pipeline by developing combination regimens, Senior VP-Worldwide Development Declan Doogan said Nov. 30
You may also be interested in...
Pfizer’s Axitinib May Have Survival Benefit Over Tarceva In Pancreatic Cancer
Pfizer's oral selective VEGF inhibitor axitinib in combination with standard chemotherapy improves overall survival by 1.3 months and decreased the risk of death by 33 percent compared to standard care in advanced pancreatic cancer patients, the firm reported during a June 4 presentation at the American Society of Clinical Oncology meeting in Chicago
Pfizer’s Axitinib May Have Survival Benefit Over Tarceva In Pancreatic Cancer
Pfizer's oral selective VEGF inhibitor axitinib in combination with standard chemotherapy improves overall survival by 1.3 months and decreased the risk of death by 33 percent compared to standard care in advanced pancreatic cancer patients, the firm reported during a June 4 presentation at the American Society of Clinical Oncology meeting in Chicago
Pfizer Better Able To De-Risk First-In-Class Compounds, R&D Head Says
Pfizer has become more effective at controlling the development risk of investigational compounds with novel mechanisms of action, Global Research & Development President John LaMattina asserted Nov. 30